A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients

American Journal of Transplantation

Volumn 5, Issue 6, 2005, Pages 1462-1468

  Humar, Atul ^a   Kumar, Deepali ^a   Preiksaitis, Jutta ^b   Boivin, Guy ^c   Siegal, Deborah ^a   Fenton, Jayne ^b   Jackson, Kathy ^b   Nia, Sarah ^a   Lien, Dale ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

Cytomegalovirus; Ganciclovir; Lung transplantation; Valganciclovir

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; GANCICLOVIR; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; VALGANCICLOVIR;

ADULT; ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DEMOGRAPHY; DRUG EFFICACY; FEMALE; GENE SEQUENCE; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEQUENCE ANALYSIS; SYMPTOMATOLOGY; VIREMIA; VIRUS LOAD;

ADMINISTRATION, ORAL; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; FEMALE; GANCICLOVIR; GRAFT SURVIVAL; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; VIREMIA; VIRUS REPLICATION;

EID: 20544467627     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.00866.x     Document Type: Article

References (27)

1. Avery RK. Special considerations regarding CMV in lung transplantation. Transpl Infect Dis 1999; 1(Suppl 1): 13-18.
2. Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transpl Infect Dis 2001; 3: 128-137.
3. Husni RN, Gordon SM, Longworth DL et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26: 753-755.
4. Falagas ME, Snydman DR, Griffith J, Werner BG. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin Infect Dis 1996; 23: 468-474.
5. Manez R, Breinig MC, Linden P et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997; 176: 1462-1467.
6. Husain S, Singh N. Bronchiolitis obliterans and lung transplantation: evidence for an infectious etiology. Semin Respir Infect 2002; 17: 310-314.
7. Cerrina J, Le Roy Ladurie F, Herve PH et al. Role of CMV pneumonia in the development of obliterative bronchiolitis in heart-lung and double-lung transplant recipients. Transpl Int 1992; 5 (Suppl 1): S242-S245.
8. Zamora MR. Cytomegalovirus and lung transplantation. Am J Transplant 2004; 4: 1219-1226.
9. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645-649.
10. Pescovitz MD, Rabkin J, Merion RM et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 2811-2815.
11. Humar A, Gregson D, Caliendo AM et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999; 68: 1305-1311.
12. Boivin G, Gilbert C, Gaudreau A, Greenfield I, Sudlow R, Roberts NA. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis 2001; 184: 1598-1602.
13. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
14. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Update 2002; 5: 88-114.
15. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
16. Zamora MR. Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation. Transpl Infect Dis 2001; 3(Suppl 2): 49-56.
17. Bailey TC, Trulock EP, Ettinger NA, Storch GA, Cooper JD, Powderly WG. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. J Infect Dis 1992; 165: 548-552.
18. Duncan SR, Grgurich WF, Iacono AT et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994; 150: 146-152.
19. Hertz MI, Jordan C, Savik SK et al. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. J Heart Lung Transplant 1998; 17: 913-920.
20. Palmer SM, Grinnan DC, Reams DB, Steele MP, Messier RH, Davis RD. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir. Clin Transplant 2004; 18: 179-185.
21. Soghikian MV, Valentine VG, Berry GJ, Patel HR, Robbins RC, Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant 1996; 15: 881-887.
22. Valantine HA, Luikart H, Doyle R et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 2001; 72: 1647-1652.
23. Weill D, Lock BJ, Wewers DL et al. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction. Am J Transplant 2003; 3: 492-496.
24. Zamora MR, Nicolls MR, Hodges TN et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004; 4: 1635-1642.
25. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185: 20-27.
26. Bhorade SM, Lurain NS, Jordan A et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 2002; 21: 1274-1282.
27. Boivin G, Goyette N, Gilbert C et al. Absence of cytomegalovirus- resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004; 189: 1615-1618.